STOCK TITAN

MannKind Corporation Participating at Upcoming Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) announced its participation in several upcoming conferences where CEO Michael Castagna will speak. Key events include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 3:30 pm EDT, the Cantor Global Virtual Healthcare Conference on September 15 at 8:40 am EDT, and the Oppenheimer Fall Healthcare Summit on September 21 at 10:50 am EDT. The presentations will be accessible through a live webcast on the company's website, with replays available for 14 days.

Positive
  • None.
Negative
  • None.

WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at upcoming conferences. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD. 

  • H.C. Wainwright 22nd Annual Global Investment Conference - Fireside Chat on Monday, September 14, 2020 at 3:30 pm (EDT)
  • 2020 Cantor Global Virtual Healthcare Conference - Fireside Chat on Tuesday, September 15, 2020 at 8:40 am - 9:10 am (EDT) 
  • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit – Fireside Chat on Monday, September 21, 2020 at 10:50 am - 11:30 am (EDT)

Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.

About MannKind Corporation

MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Company Contact:
818-661-5000
ir@mannkindcorp.com

Source: MannKind Corporation


FAQ

What conferences is MannKind Corporation participating in September 2020?

MannKind Corporation will participate in the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, the Cantor Global Virtual Healthcare Conference on September 15, and the Oppenheimer Fall Healthcare Summit on September 21.

Who will represent MannKind Corporation at the upcoming conferences?

CEO Michael Castagna will represent MannKind Corporation at the upcoming conferences.

When is the H.C. Wainwright Conference where MannKind will present?

The H.C. Wainwright 22nd Annual Global Investment Conference will take place on September 14, 2020, at 3:30 pm EDT.

How can I access the MannKind Corporation conference presentations?

You can access the live webcast of MannKind's conference presentations via the News & Events section of their website at www.mannkindcorp.com.

What is the focus of MannKind Corporation's business?

MannKind Corporation focuses on developing and commercializing inhaled therapeutic products for diabetes and orphan lung diseases.

Mannkind Corporation

NASDAQ:MNKD

MNKD Rankings

MNKD Latest News

MNKD Stock Data

1.84B
270.76M
1.83%
56.64%
15.24%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DANBURY